|
|
|
|
|
|
|
Highlights from the 2023 European Society for Medical Oncology Annual Meeting
|
|
|
|
|
|
Optimising Overall Survival in Advanced Renal Cancer
|
|
| Evolving Frontline Treatment Paradigms in Advanced RCC
|
| Toni K. Choueiri, MD
|
| In this presentation, Toni Choueiri delves into the evolving frontline treatment paradigms for advanced Renal Cell Carcinoma (RCC). He discusses key trials involving immunotherapy and VEGF inhibitors, emphasizing the importance of personalized care and highlighting emerging RCTs in non-clear cell RCC.
|
|
|
|
|
|
| What is the Role of Localized Therapies in Metastatic Renal Cell Carcinoma (RCC)?
|
| Axel Bex, MD, Ph.D.
|
| In this presentation, Axel Bex discusses the role of localized therapies for metastatic RCC. Localized treatments offer the potential for cure, improved survival, and reduced systemic therapy. The evidence mainly comes from retrospective studies on metastasectomies, with ongoing trials aiming to provide more insights into the effectiveness of localized therapies.
|
|
|
|
|
|
| New Therapeutic Targets in Advanced RCC and Data from Sequencing Trials
|
| Cristina Suárez Rodríguez, MD, Ph.D.
|
| Cristina Suarez Rodriguez discusses therapeutic targets and data from sequencing trials for advanced renal cell carcinoma (RCC). Key points included definitions of primary and secondary resistance to immune checkpoint inhibitors, as well as considerations for treatment sequencing after various combinations.
|
|
|
|
|
|
|
Proffered Paper Session - Genitourinary Tumors, Prostate
|
|
| RADICALS RT Final Results: Timing of Radiotherapy After Radical Prostatectomy Randomised Controlled Trial
|
Noel Clarke, MBBS, FRCS, ChM
|
| Noel Clarke presents the final results of the RADICALS RT trial, addressing the optimal timing of radiotherapy post-radical prostatectomy. This study found that early salvage radiotherapy is as effective as adjuvant radiotherapy in terms of long-term freedom from distant metastasis and overall survival, with early salvage causing lower urinary and bowel morbidity.
|
|
|
|
|
|
|
|
|
|
|
| STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients With Metastatic Castration-Resistant Prostate Cancer Interim Results Phase 1 AMG 509 (Xaluritamig)
|
| William Kelly, DO
|
| William Kelly presents interim results from a phase 1 study of Xaluritamig in patients with metastatic castration-resistant prostate cancer. Xaluritamig, a T-cell engager targeting STEAP1, showed encouraging antitumor activity in heavily pre-treated mCRPC patients. Dose expansion and optimization are ongoing for further development of Xaluritamig as a monotherapy and in combination.
|
|
|
|
|
|
| Invited Discussant: Final Results of RADICALS RT & Interim Results from a Phase 1 Study of AMG 509 in mCRPC
|
| Shahneen Sandhu, MBBS FRACP
|
| Shahneen Sandhu's discussant presentation highlights key findings. She discusses adjuvant vs. salvage radiotherapy in high-risk prostate cancer leans toward early salvage to mitigate morbidity, with the potential to personalize treatment using PSMA PET imaging. Additionally, she discussed the promise of T-cell engagers like xaluritamig in mCRPC, emphasizing the need for improved toxicity profiles and exploring combinations for enhanced efficacy.
|
|
|
|
|
|
| Enzalutamide and 177Lu-PSMA-617 in Poor-Risk Metastatic Castration-Resistant Prostate Cancer (mCRPC), a Randomized, Phase 2 Trial
|
| Louise Emmett, MBChB, FRACP, MD
|
| Louise Emmett presents promising findings from the ENZA-p (ANZUP 1901) trial, a phase 2 study combining enzalutamide with adaptive-dosing of 177Lu-PSMA-617 in poor-risk mCRPC. The results showed enhanced anticancer activity with significant improvements in PSA-PFS, offering a new treatment option for patients with metastatic prostate cancer.
|
|
|
|
|
|
| Refining Risk Stratification in Patients Undergoing Radiotherapy and Long-Term ADT for High-Risk/Locally Advanced Prostate Cancer: An Individual Patient Data Analysis of RCTs from the ICECaP Consortium
|
| Praful Ravi, MB, BChir, MRCP
|
| Praful Ravi presented research on refining risk stratification in patients with high-risk/locally advanced prostate cancer undergoing radiotherapy and long-term ADT. The study identified independent prognostic factors, including Gleason score, clinical stage, and PSA levels, that can help guide treatment decisions. Patients with specific risk factors are likely to benefit from treatment intensification beyond standard therapy, providing valuable insights for future clinical trials in this population.
|
|
|
|
|
|
| Invited Discussant: Is More Always Better?
|
| Daniel Heinrich, MD
|
| In this presentation, Daniel Heinrich discusses the question of whether "more is always better" in the context of prostate cancer treatments. He highlighted the impressive outcomes seen with combination therapies, such as ADT + darolutamide + docetaxel in metastatic hormone-sensitive prostate cancer and olaparib + abiraterone in metastatic castration-resistant prostate cancer. However, he also raised concerns about the potential impact of multiple treatments on patients' quality of life and healthcare systems.
|
|
|
|
|
|
|
|
|
|
|
|
